Why is the sustained virological response rate among HCV genotype 3 infected patients in Pakistan low?

Journal of the College of Physicians and Surgeons Pakistan

Volumn 22, Issue 1, 2012, Pages 70-

  Alavian, Seyed Moayed ^a   Shafiei Guilani, Mostafa ^b   Aalaei Andabili, Seyed Hossein ^b  

^a Gastroenterology and Liver Disease   (Iran)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT;

BLOOD TRANSFUSION; BODY MASS; BODY WEIGHT; CASE CONTROL STUDY; DENTAL PROCEDURE; GENOTYPE; HEPATITIS B; HEPATITIS C; HUMAN; INFECTION RISK; INJECTION; INSULIN RESISTANCE; LETTER; MICROBIOLOGICAL PARAMETERS; NONHUMAN; PAKISTAN; PUBLIC HEALTH PROBLEM; RISK ASSESSMENT; SUSTAINED VIROLOGICAL RESPONSE RATE; VIRUS LOAD; FEMALE; GENETICS; HEPATITIS C VIRUS; MALE; NOTE;

ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE;

EID: 84862338128     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (7)

1. Qureshi S, Batool U, Iqbal M, Burki UF, Khan NU. Pre-treatment predictors of response for assessing outcomes to standard treatment in infection with HCV genotype 3. J Coll Physicians Surg Pak 2011; 21:64-8.
2. Alavian SM, Fallahian F. Comparison of seroepidemiology and transmission modes of viral hepatitis C in Iran and Pakistan. Hepatol Monthly 2008; 8:51-9.
3. Umar M, Khaar HT, Khurram M, Hasan Z. Anti-HCV antibody positivity of various sections of Pakistani patients. J Coll Physicians Surg Pak 2009; 19:737-41.
4. Deltenre P, Louvet A, Lemoine M, Mourad A, Fartoux L, Moreno C, et al. Impact of insulin resistance on sustained response in HCV patients treated with Pegylated interferon and ribavirin: a metaanalysis. J Hepatol 2011 Apr 13. [Epub ahead of print]
5. Aziz S, Qamar R, Ahmed I, Imran K, Masroor M, Rajper J, et al. Treatment profile of hepatitis C patients: a comparison of interferon alpha 2a and 2b treatment regimes. J Coll Physicians Surg Pak 2010; 20:581-5.
6. Munir S, Saleem S, Idrees M, Tariq A, Butt S, Rauff B, et al. Hepatitis C treatment: current and future perspectives. Virol J 2010; 7:296.
7. Sarrazin C, Susser S, Doehring A, Lange CM, Muller T, Schlecker C, et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011; 54:415-21.